Postmarketing Analysis of Lovastatin Use in the VA Northern California System of Clinics: A Retrospective, Computer-Based Study

American Journal of Managed Care

Volumn 3, Issue 10, 1997, Pages 1537-1545

  Swislocki, Arthur L M ^a,b,c   Lin, Kim ^a,b   Cogburn, Diane ^a   Fann, Karen Y ^a,b   Khuu, Duke T ^a,b   Noth, Robert H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

AGED; ARTICLE; BLOOD; CLINICAL CHEMISTRY; DRUG USE; FEMALE; HUMAN; MALE; MEDICAL AUDIT; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PUBLIC HOSPITAL; UNITED STATES;

AGED; ANTICHOLESTEREMIC AGENTS; CALIFORNIA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL CHEMISTRY TESTS; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALS, VETERANS; HUMANS; LOVASTATIN; MALE; MEDICAL AUDIT; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES;

EID: 0031244515     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. Shott S. Statistics for Health Professionals. Philadelphia: WB Saunders; 1990.
3. Rubinstein A, Lurie Y, Groskop I, Weintrob M. Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dL (5.18 to 6.21 mmol/liter). Am J Cardiol 1991;68: 1123-1126.
4. Lovastatin Study Group. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 1993;153:1079-1087.
5. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82(5 suppl):IV281-IV283.
6. Bates MC, Warren SG, Grubb S, Chillag S. Effectiveness with low-dose lovastatin in lowering serum cholesterol. Experience with 56 patients. Arch Intern Med 1990; 150:1947-1950.
7. La Rosa JC, Applegate W, Crouse JR 3rd, et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994;154:529-539.
8. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Study (MARS). Ann Intern Med 1993;119:969-976.
9. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Therap 1994;16:366-385.
10. Jacob BG, Richter WO, Schwandt P. Long-term treatment (2 years) with the HMG-CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. J Cardiovasc Pharmacol 1993;22:396-400.
11. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
12. Kruse W, Nikolaus T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993;45:211-215.
13. Montanaro M, Magrini N, Vaccheri A, Battilana M. Drug utilization in general practice: Prescribing habits of National Formulary drugs by GPs of Emilia Romagna (Italy) in 1988 and 1989. Eur J Clin Pharmacol 1992;42:401-408.
14. Wysowski DK, Kennedy DL, Gross TP. Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988. JAMA 1990;263:2185-2188.
15. Lintott CJ, Scott RS. HMG-CoA reductase inhibitor use in the aged. Drugs Aging 1992;2:518-529.
16. Cheng H, Rogers JD, Sweany AE, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992;9:1629-1633.
17. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lov astatin. Am J Med 1991;91(1B):25S-30S.
18. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol 1990;65:23F-26F.
19. Mantell G, Burke MT, Staggers J. Extended clinical safety profile of lovastatin. Am J Cardiol 1990;66:11B-15B.
20. Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 1990;77(suppl 4):58-65.
21. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
22. Manoukian AA, Bhagavan NV, Hayashi T, et al. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990;36:2145-2147.
23. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994;39:2032-2033.
24. Ballare M, Campanini M, Airoldi G, et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol Dietol 1992; 38:41-44.
25. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789-796.
26. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265:1145-1151.
27. Pool JL, Shear CL, Downton M, et al. Lovastatin and coadministered antihypertensive/cardiovascular agents. Hypertension 1992;19:242-248.